Human evidence for vasoactive intestinal peptide spans respiratory failure trials, Continual lung disease scientific tests, CIRS cohorts, and observational biomarker data — a broader clinical proof foundation than most peptides in current study.Just with outcome sizes 30–40% smaller sized than prophylactic protocols. Pre-treatment permits VIP t